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ABSTRACT 
The formulation of novel therapeutic proteins is a challenging task which aims at finding formulation 
conditions that will minimize protein degradation during long-term storage. One particularly important 
and difficult-to-predict protein degradation pathway is the so-called non-native aggregation. The 
qualitative and quantitative prediction of the latter has been a subject of extensive research over the 
past two decades. An increasing body of evidence shows that the widely-used short-term biophysical 
techniques cannot accurately rank formulation conditions in order of their effect on the aggregation 
during long-term storage of some therapeutic proteins, e.g. monoclonal antibodies. Here we suggest 
a novel approach for the selection of formulation conditions that will suppress the formation of protein 
aggregates during long-term storage. We postulate that conditions (i.e. pH, buffer type, ionic strength) 
that reduce the isothermal aggregation of various denaturant-induced partially folded protein species 
will be conditions that impede protein aggregation during long-term storage. To test our hypothesis, 
we developed an isothermal microdialysis-based unfolding/refolding assay, named ReFOLD, which we 
use to induce moderate aggregation of partially folded proteins. Next, we assessed the relative 
monomer yield after isothermal unfolding/refolding of two monoclonal antibodies, each formulated 
in 12 different conditions. Using the proposed approach, we were able to accurately rank the 
formulations in order of their effect on the amount of protein aggregates detected after storage for 
12 months at 4 ⁰C and 25 ⁰C, while widely-used stability-indicating parameters like protein melting and 
aggregation onset temperatures failed to provide accurate predictive formulation rankings.  
 
 
 
 
 
2 
 
GRAPHICAL ABSTRACT 
 
KEYWORDS 
Proteins; Protein formulation; Protein folding; Protein unfolding; Protein Aggregation; Monoclonal 
antibody; Storage Stability; Stability prediction; 
ABBREVIATIONS 
CD – Circular dichroism; 
dG – the Gibbs free energy of protein unfolding; 
DLS – Dynamic Light Scattering; 
DSF - Differential Scanning Fluorimetry; 
ICD – Isothermal Chemical Denaturation; 
mAb – monoclonal antibody; 
nanoDSF™ – Microscale Differential Scanning Fluorimetry; 
RMY – Relative Monomer Yield after refolding; 
SEC-MALS – size exclusion chromatography coupled to a multi-angle light scattering detector; 
Tagg – Protein aggregation onset temperature; 
Tm – Protein melting temperature; 
 
 
 
3 
 
1. INTRODUCTION 
Non-native protein aggregation (referred to as just “protein aggregation” in this paper) is a major 
concern during the long-term storage of liquid protein formulations1–4. This pathway of protein 
aggregation typically occurs through partially unfolded intermediates (often termed as reactive 
species5), which can form irreversible aggregate nuclei that can further grow by various mechanisms. 
The latter are extensively discussed in the literature and are outside the scope of this article1,6–9. 
Regardless of the exact mechanism of aggregate nucleation and growth, the formation and presence 
of protein aggregates in parenteral products should be controlled and minimized for various reasons, 
e.g. immunogenicity concerns10–13, reduced biological activity14,15 or non-compliance with regulatory 
frameworks16–18. The formation of protein aggregates during long-term storage can be suppressed by 
choosing suitable formulation conditions, e.g. pH, buffer type, ionic strength, etc.19,20. The process of 
selecting the optimal formulation for a new therapeutic protein candidate usually includes the testing 
of dozens of different conditions21,22. Screening all these formulation conditions with long-term and/or 
accelerated stability studies is impractical as this would require a lot of resources. Therefore, many 
researchers turn to short-term biophysical techniques that could provide predictions for the protein 
aggregation during storage, thereby reducing the number of formulations for long-term stability 
studies.  
Such biophysical techniques usually require small amounts of sample, can be performed in short 
timeframes and are suitable for automatization and high-throughput formats23–26. Two of these 
techniques that are frequently used in the industry are differential scanning fluorimetry (DSF) and 
dynamic light scattering (DLS)4,27–32. The latter can provide the (apparent) protein melting temperature 
(Tm) and the aggregation onset temperature (Tagg) respectively. Earlier publications show that in some 
cases, and on a limited set of formulation conditions, a high Tm or a high Tagg can be an indicator for 
formulation conditions where protein aggregation is suppressed during accelerated stability studies 
(e.g. 40 ⁰C and 50 ⁰C)4,33,34. However, recent work on larger sets of proteins indicates that these 
parameters show a very weak or no correlation with the aggregation behaviour of many therapeutic 
proteins, especially mAbs, during storage at 4 ⁰C and 25 ⁰C21,33,35,36.  
Probably due to the above-mentioned reason, researchers have started to explore orthogonal 
techniques that could provide better stability predictions for the aggregation behaviour of novel 
therapeutic proteins during long-term storage. One such technique is isothermal chemical 
denaturation (ICD)31,37,38. Although ICD is the gold standard to obtain the Gibbs free energy of protein 
unfolding (and thereby assess the conformational stability of a protein)39, the data evaluation from this 
method is valid only in cases where the protein of interest undergoes reversible unfolding in the 
denaturant solution40–42. Most of the published work including ICD experiments is on small globular 
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single-domain proteins43–45. However, the vast majority of therapeutic proteins under development in 
the moments have large, multi-domain structures (e.g. mAbs, bispecifics, fusion proteins, antibody-
drug conjugates) that can undergo complex, multi-step unfolding during an ICD experiment which 
could require sophisticated fitting to a model31,46. Furthermore, the reversibility of unfolding of these 
proteins in different formulation conditions might vary37,40,41. Recently, it was suggested that one could 
use ICD experiments to investigate non-reversibility effects during protein unfolding in a 
denaturant47,48. Such experiments study how the apparent Gibbs free energy of protein unfolding 
changes when different protein concentrations are used to obtain the ICD curves. It was already 
demonstrated that the latter approach can provide complementary stability-indicating information to 
DSF and DLS37,49. Still, ICD experiments that study the concentration dependence of dG are tedious, 
require dedicated laboratory equipment and rely on the quality of the fitting to a certain unfolding 
model. 
Rather than using ICD as an “indirect” way to look into the effect of the formulation conditions on the 
reversibility of isothermal protein unfolding, we recently suggested that one could directly study the 
aggregation after dilution from a denaturant40. Shortly after that and independently of us, Rowe et al. 
suggested a similar approach50. In our previous work, we showed that when the dilution refolding 
experiments are performed with certain denaturant concentrations, the protein aggregation during 
refolding can be linked to other stability-indicating parameters, e.g. the melting denaturant 
concentration Cm and the interaction parameter kD40. The dilution approach we proposed is valuable 
to probe which denaturant concentrations will cause extensive protein aggregation after dilution 
refolding and also to study if there is a difference in the physical stability of a protein in conditions with 
overlapping ICD curves40.  
However, different concentrations of a denaturant cause different degrees of protein unfolding and 
different aggregation-prone intermediates. Each of the latter could be important for the non-native 
protein aggregation during long-term storage. Rather than diluting the protein from dozens of 
different denaturant concentrations, we decided to perform microdialysis on the protein against a 
denaturant and subsequently against a denaturant-free formulation buffer. This procedure will cause 
various unfolding (refolding) protein intermediates. We hypothesized that these intermediates will 
aggregate depending on the formulation conditions, e.g. pH, buffer type, ionic strength, protein 
concentration. The rationale behind using this phenomenon as a protein formulation tool is that 
formulation conditions which suppress the aggregation of various partially folded states would be 
formulation conditions that would suppress protein aggregation during long-term storage. Since the 
isolation of the individual aggregation-prone intermediates or aggregates formed could be a 
challenging task, we adopted an approach where we assess the relative monomer yield (RMY) after 
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the isothermal unfolding and refolding is completed. Important to note, assessing the RMY after 
isothermal unfolding/refolding of the protein for the purpose of formulation development would be 
quite different compared to unfolding/refolding experiments to increase the monomer yield after 
protein expression as inclusion bodies. The latter experiments usually include a reduction and new 
formation of disulphide bonds, as well as extremities in the pH, excipient concentration and the type 
of excipients used51–55. Assessing the aggregation during isothermal unfolding/refolding of the protein 
as a formulation tool is focused on a pH range which is realistic for long-term storage and 
administration in patients due to chemical stability and tolerability considerations respectively. 
Furthermore, the excipients used, as well as their concentrations, would be approved for parenteral 
application56.  
To study our hypothesis, we developed a microdialysis unfolding/refolding assay which we called 
ReFOLD. Next, we studied the effect of realistic for long-term storage formulation conditions on the 
relative monomer yield after isothermal unfolding/refolding of two monoclonal antibodies. We 
validated the predictions from the ReFOLD assay by performing 12-month stability study at 4 ⁰C and 
25 ⁰C. Additionally, we characterized the antibodies in the presence of urea to show that this 
denaturant causes partially unfolded states and suppresses the protein aggregation in all conditions 
tested. The latter phenomena allow us to see formulation-dependent differences in the monomer loss 
caused by aggregation of partially folded protein species during unfolding/refolding.  
2. MATERIALS AND METHODS 
2.1. Monoclonal antibodies and chemicals 
Two IgG1 monoclonal antibodies were used in this work - LMU-1 and PPI03. The monomeric state and 
the purity of the proteins in the bulk solution were confirmed as described earlier40. 
The buffer of the mAbs was exchanged by extensive dialysis overnight as previously described40. Unless 
otherwise stated, the final mAb solutions after dialysis contained 10 mM histidine/histidine 
hydrochloride buffer, 10 mM sodium citrate/citric acid buffer with a pH 5, 5.75 or 6.5. The PPI03 
samples containing 70 mM sodium chloride were prepared by spiking in the salt from a 10X stock 
solution. All LMU-1 samples contained 0,05 % w/v polysorbate 20 which was spiked in the protein 
solution after dialysis. All PPI03 solutions were free of surfactants. For an overview of the formulations 
see Tables 1, S1 and S2. The protein concentration was measured by UV spectrometry at 280 nm with 
a Nanodrop 2000 (Thermo Fisher Scientific, Wilmington, DE) using the respective protein extinction 
coefficient. 
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Reagent chemicals from the highest grade available were purchased from Sigma Aldrich (Steinheim, 
Germany), VWR International (Darmstadt, Germany) or Fisher Scientific (Schwerte, Germany). Highly 
purified water was used for the preparation of all buffers. 
2.2. Isothermal protein unfolding and refolding with microdialysis (the ReFOLD assay)  
100 µL of formulated mAb solution was filled in Pierce™ microdialysis devices with a membrane having 
3.5 kDa MWCO. The samples were dialyzed in a deep well-plate against 1.5 mL of 10 M urea solution 
in the respective formulation buffer. The urea solution was changed 4 and 8 hours after the beginning. 
After the last change, the dialysis was continued for another 16 hours. Next, the mAb samples dialyzed 
against 10 M urea were dialyzed against 1.5 mL of the respective urea-free formulation buffer. The 
buffer was changed 4 and 8 hours after the beginning, the dialysis continued in total for 24 hours. 
During the entire dialysis procedure, the deep well plate was attached to a Thermomixer Comfort 
(Eppendorf AG, Hamburg, Germany) which was adjusted to agitate the plate at 700 rpm. Finally, the 
samples were collected from the dialysis devices and the weight of each sample was added to 1.0 g 
with the respective urea-free buffer to avoid variations in the sample volume that might arise during 
dialysis. Finally, the samples were centrifuged at 10 000 x g for 10 minutes to remove any insoluble 
matter. The supernatant was used for further measurements. 
2.3. Size Exclusion Chromatography (SEC) 
A Dionex Summit 2 system (Thermo Fisher, Dreieich, Germany) and a TSKgel G3000SWxl, 7,8x300 mm, 
5 µm column (Tosoh Bioscience, Tokyo, Japan) were used for the size exclusion chromatography. 
Protein elution was detected at 280 nm unless otherwise stated. The running buffer consisted of 100 
mM potassium phosphate, 200 mM sodium chloride and 0,05 % w/v sodium azide. The buffer pH was 
adjusted to 7.0 with 2 M sodium hydroxide. The chromatograms were integrated with Chromeleon 
V6.8 (Thermo Fisher, Dreieich, Germany). The relative content of the high molecular weight (HMW) 
species formed after long-term storage was calculated by dividing the peak area of the high molecular 
weight species by the total area of all protein peaks in the chromatogram which provides a number 
representing the relative content of high molecular weight species in percentage. Representative 
chromatograms with integration times and more explanations are presented in Fig S1. The relative 
monomer yield (RMY) of the proteins after isothermal unfolding/refolding, i.e. the ReFOLD assay, was 
calculated by dividing the area of the monomer peak of the refolded sample by the area of the 
monomer peak of the sample before unfolding/refolding which gives a value between 0 and 1, where 
0 means that no protein monomer is recovered in the sample after refolding and 1 means the same 
amount of monomer is recovered after refolding. 
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2.4. Size Exclusion Chromatography with Multi-angle Light Scattering Detector (SEC-MALS) 
An Agilent 1100 Series HPLC system (Santa Clara, CA, USA) with an Agilent 1100 multiple wavelength 
detector (Santa Clara, CA, USA), Agilent 1100 refractive index detector and a DAWN HELEOS multi-
angle light scattering (MALS) detector (Wyatt Technology, Santa Barbara, USA) were used for the SEC-
MALS measurements. Sample elution was monitored at 280 nm and with the change in the refractive 
index. The same column and running buffer like for the SEC method above were used. Data collection 
and processing were performed using the ASTRA software, Version 7.1 (Wyatt Technology, Santa 
Barbara, USA). 
2.5. Isothermal Chemical Denaturation (ICD) 
Samples for isothermal chemical denaturation experiments were prepared by combining protein stock 
solution in formulation buffer with different amounts of formulation buffer and 10 M urea stock 
solution in formulation buffer in a non-binding 384-well plate as described earlier37,40. The samples 
were incubated for 24 hours at room temperature and the protein intrinsic fluorescence intensity at 
330 and 350 nm was measured after excitation at 280 nm with a FLUOstar Omega microplate reader 
(BMG Labtech, Ortenberg, Germany). The intrinsic protein fluorescence intensity ratio (FI350/FI330) 
was plotted against the urea concentration to obtain isothermal chemical unfolding curves of the mAbs 
in different buffers25,37,40.  
2.6. Microscale Differential Scanning Fluorimetry (nanoDSF™) 
The protein samples were filled in standard nanoDSF™ grade capillaries, the capillaries were sealed 
and the thermal unfolding of the proteins was studied by applying a temperature ramp of 1 ⁰C/min 
from 20 to 100 ⁰C with the Prometheus NT.48 (NanoTemper Technologies, Munich, Germany) system 
that measures the intrinsic protein fluorescence intensity at 330 and 350 nm after excitation at 280 
nm. At the same time, the device detects aggregation/precipitation of the samples by measuring the 
back-reflection intensity of a light beam that passes twice through the capillary, this signal can be 
normalized to a value called “Excess Scattering”. The apparent protein melting temperatures (Tm) were 
determined with the PR.ThermControl software V2.1 (NanoTemper Technologies, Munich, Germany) 
from the maximum of the first derivatives of the thermal unfolding curves57,58.  
2.7. Circular Dichroism (CD) Spectroscopy 
Near-UV circular dichroic spectra of the mAb samples were measured at 25 ⁰C with a Jasco J-810 
spectrometer (JASCO Deutschland GmbH, Pfungstadt, Germany). Quartz cuvettes (Hellma GmbH, 
Muellheim, Germany) with 10 mm wavelength path were used for the measurements. All 
measurements were performed with 3 accumulations and a speed of 20 nm/min. The spectrum of the 
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respective buffer was subtracted for each sample, Savitzky-Golay algorithm with 9 smoothing points 
was applied and the mean residue ellipticity (MRE) of the protein at each wavelength was calculated 
as described elsewhere59. 
2.8. Fourier-transform Infrared Spectroscopy (FT-IR) 
FT-IR spectra of the mAb samples were collected at 25 °C using a Tensor 27 (Bruker Optik GmbH, 
Ettlingen, Germany) with a BioATR (Attenuated Total Reflectance) cell™ II (Harrick) connected to a 
thermostat (DC30-K20, Thermo Haake). 120 scans with a resolution of 4 cm-1 were taken to measure 
each spectrum. The raw data of each sample was analysed with the Opus 7.5 (Bruker Optik GmbH) 
software and shown as a vector-normalized second-derivative spectrum. The data were smoothed 
using a Savitzky-Golay algorithm with 17 smoothing points60. 
2.9. Long-term stability studies 
The mAb solutions with different formulation conditions were sterile filtered with a 0.22 µm cellulose 
acetate filter and aseptically filled into pre-sterilized DIN2R glass type I vials (MGlass AG, Germany). 
Next, the vials were crimped with rubber chlorobutyl stoppers with FluroTec® coating (West 
Pharmaceutical Services, USA) and stored at 4 ⁰C and 25 ⁰C for the desired time. Three different vials 
were used for the SEC analysis of each condition. 
3. RESULTS AND DISCUSSION 
3.1. The isothermal protein unfolding/refolding leads to a formulation-dependent protein 
aggregation and monomer loss 
Both antibodies used in this work show substantial aggregation after microdialysis against 10 M urea 
(unfolding) and subsequently against urea-free formulation buffer (refolding). The visual appearance 
of the samples after refolding is dependent on the formulation conditions in which the refolding is 
performed. For example, after the ReFOLD assay, LMU-1 formulations with a concentration 10 g/L in 
10 mM histidine buffer with pH 6.5 remain transparent, while counterparts with 10 mM citrate buffer 
show increased turbidity and form a pellet after centrifugation. These observations confirm earlier 
reports that the aggregate formation of antibodies after dilution/dialysis from a denaturant is 
formulation-dependent40,50. SEC-MALS analysis of the supernatant of the refolded samples shows that 
the samples contain a considerable amount of high molecular weight species ranging from dimers to 
oligomers larger than 1000 kDa. (Figure 1). The aggregates are not reversible, and their relative area is 
the same even several days after the dialysis (data not shown). A monomer peak having the same 
retention time as the native protein is detected in the refolded samples. The area of the monomer 
peak is largely dependent on the formulation buffer in which the ReFOLD assay is performed. Since the 
evaluation of the exact size, concentration and type of aggregates formed is challenging in such a 
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complex mixture, we decided to focus on the fraction of the protein that remains monomeric after 
isothermal unfolding/refolding (i.e. the relative monomer yield - RMY) as a parameter providing a 
comparison between the formulations. 
Figure 1. SEC-MALS of native and refolded samples of LMU-1 and PPI03.  
 
3.2. The relative monomer yield after isothermal protein unfolding/refolding correlates with the 
relative amount of protein aggregates detected after long-term storage 
The relative monomer yield after the ReFOLD assay is highly dependent on the formulation conditions 
of both LMU-1 (Table 1 and S1) and PPI03 (Table S2). The formulation conditions also have an influence 
on the relative area of high molecular weight (HMW) species, i.e. protein aggregates, detected by SEC 
after storing the respective denaturant-free protein samples for 12 months at 4 ⁰C and 25 ⁰C (Tables 
1, S1 and S2). LMU-1 samples contain more HMW species after long-term storage compared to PPI03. 
Both proteins form fewer HMW species when stored at 4 ⁰C compared to storage at 25 ⁰C. We also 
used flow microscopy to study the presence of subvisible particles in the samples after 12 months of 
storage at 4 ⁰C and 25 ⁰C (Figure S2). Calculations on the monomer recovery from the size-exclusion 
chromatography method used for the stability study are also included in supplementary data (Tables 
S3 and S4). A very strong correlation between the relative monomer yield from the ReFOLD assay and 
the relative area of high molecular weight species detected after 12 months of storage is observed in 
the case of LMU-1 (Figure 2). Interestingly, the first and second apparent melting temperatures of 
LMU-1 measured nanoDSF™ show reversed correlations with the relative area of HMW species 
detected after storage, therefore providing misleading predictions for the long-term physical stability 
of these samples (Figures S3 and S4). The aggregation onset temperatures of LMU-1 show only a 
moderate to weak correlation with the amount of aggregates formed after storage for 12 months 
(Figure S5). In the case of PPI03 the Spearman's R between the RMY from the ReFOLD assay and the 
aggregates formed after storage at 4 ⁰C and 25 ⁰C is -0.762 and -0.686 respectively, showing a strong 
correlation between these parameters (Figure S6). Like the case of LMU-1, the melting temperatures 
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of the PPI03 samples show an inverse correlation with the aggregates formed after storage, therefore 
providing wrong predictions for these formulations (Figures S7 and S8). The aggregation onset 
temperatures of the PPI03 samples show a very weak correlation with the amount of high molecular 
species formed after long-term storage at 4 ⁰C and 25 ⁰C (Figure S9). In general, PPI03 exhibits a very 
low aggregation propensity and small differences between the formulations during long-term storage. 
The latter observations can contribute to the lower correlation between the RMY and the aggregates 
formed after 12 months of storage in comparison to LMU-1. Almost all  
LMU-1 and PPI03 formulations contain less than 10 000 particles ≥ 2 µm per mL after 12 months of 
storage at 25 ⁰C and 4 ⁰C (Figure S2). One exception is the LMU-1 formulation with protein 
concentration 50 g/L formulated in 10 mM histidine pH 6.5 which contains around 150 000 particles  
≥ 2 µm per mL. Interestingly, this is also the formulation with the lowest relative monomer yield after 
the ReFOLD assay (Table 1). There, are small differences, i.e. ± 5 %, in the monomer recovery of the 
antibodies at the end of the stability study. The samples with high RMY from the ReFOLD assay show 
100 % (± 1 %) monomer recovery after 12-month storage at 4 ⁰C and 25 ⁰C (Tables S3 and S4). 
It is important to underline that the RMY-based predictions from the ReFOLD assay provide reliable 
ranking of the formulations in order of their effect on the relative area of protein HMWs formed after 
12 months of storage at 4 ⁰C and 25 ⁰C, while often-used stability-indicating parameters (i.e. apparent 
protein melting temperatures from nanoDSF™ and the aggregation onset temperatures from dynamic 
light scattering) provided misleading or weak predictions. 
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Table 1. Relative Monomer Yield (RMY) of LMU-1 formulations after the ReFOLD assay and the 
relative content of high molecular weight species after long term storage of the respective LMU-1 
formulations. The values are mean of triplicates and the error represents the standard deviation. 
The value from each replicate is provided in Table S1. 
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
Mean StDev Mean StDev Mean StDev 
1 10 histidine 5 0.387 0.0145 0.207 0.0252 0.153 0.0513 
2 10 histidine 5.75 0.378 0.0125 0.167 0.0153 0.197 0.0462 
3 10 histidine 6.5 0.269 0.0035 0.447 0.0907 0.283 0.0808 
4 10 citrate 5 0.241 0.0021 0.51 0.0346 0.313 0.0231 
5 10 citrate 5.75 0.168 0.0032 0.723 0.0651 0.363 0.0586 
6 10 citrate 6.5 0.159 0.0067 0.94 0.1082 0.607 0.0404 
7 50 histidine 5 0.096 0.0032 0.703 0.0289 0.47 0.04 
8 50 histidine 5.75 0.083 0.0046 0.863 0.0306 0.587 0.0723 
9 50 histidine 6.5 0.005 0.0038 1.607 0.0551 0.923 0.0208 
10 50 citrate 5 0.071 0.0052 0.977 0.0808 0.437 0.0643 
11 50 citrate 5.75 0.035 0.0046 1.15 0.0819 0.593 0.0208 
12 50 citrate 6.5 0.021 0.0032 1.757 0.0929 1.01 0.0755 
 
Figure 2. Correlation between the relative monomer yield of LMU-1 from the ReFOLD assay and the 
relative content of high molecular weight species, i.e. protein aggregates, detected by size exclusion 
chromatography after 12 months of storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each 
replicate is shown on the graph. The solid red line is linear fit of the data, the dark red zone 
represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction interval. 
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3.3. Urea causes partially unfolded species, reduces the melting temperatures and suppresses the 
aggregation of LMU-1 and PPI03 
To study whether the proteins in this work form partially folded states in urea, we performed 
isothermal chemical denaturation experiments on all 24 LMU-1 and PPI03 formulations. The 
isothermal unfolding curves of LMU-1 (Figure 3) and PPI03 (Figure S10) are dependent on the 
formulation conditions (i.e. pH, buffer type, sodium chloride concentration). However, in all conditions 
tested the intrinsic protein fluorescence ratio reached the same value at urea concentration of 9.5 M 
(around 1.3 in the case of LMU-1 and around 1.2 in the case of PPI03). This indicates that the unfolding 
was complete at this concentration of urea. The latter was also later confirmed by the loss of the typical 
peaks in the near-UV CD spectra related to the protein tertiary structure (see below). Our aim by 
performing the isothermal chemical denaturation experiments was not to fit the data and extract 
thermodynamic parameters from it. Our purpose was to show that different concentrations of urea 
cause different states of the unfolding of the protein in the formulations tested. 
Figure 3. Isothermal unfolding curves of LMU-1 in different formulation buffers. The symbols are 
means of triplicates and the bars represent the standard deviation. The lines are a guide to the eye. 
The concentration of LMU-1 in all samples is 1 g/L. 
 
Further, we studied how urea affects the melting temperatures and the aggregation behaviour of the 
protein with nanoDSF™. Moderate urea concentrations (up to 4.5 M) shift the apparent melting 
temperatures of both proteins to a lower temperature, while higher urea concentrations (6-7.5 M) 
cause partial protein unfolding at room temperature (Figures 4 and S11). A similar effect of urea on 
the melting temperatures of a mAb was reported from differential scanning calorimetry experiments61. 
No unfolding upon heating is detected in 9.5 M urea, indicating that the proteins are already unfolded 
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at 20 ⁰C in this urea concentration (Figures 4 and S11). This is in a good agreement with the ICD (Figure 
3 and S10) and the near-UV circular dichroism data (see below). The latter observations are consistent 
among all 24 formulations in this work (data not shown). These results confirm our hypothesis that 
different urea concentrations (which the protein will inevitably experience during the ReFOLD assay) 
cause various partially folded protein species in all formulations tested here. 
Additionally, we observed that an increasing concentration of urea suppresses the aggregation of the 
mAbs even at high temperatures (Figures 4 and S11). Similar observations were reported earlier for 
another antibody61. No protein aggregation was detected with the Prometheus NT.48 during the 
temperature ramp when the protein was in solutions with 5 to 9.5 M urea (Figure 4 and S11), while 
rapid aggregation was observed around 70-80 ⁰C in the urea-free LMU-1 and PPI03 formulations. We 
should note that the nature of the aggregate detection with the Prometheus NT.48 allows us to see 
only aggregates with a size starting from about 40-50 nm. Therefore, we cannot conclude that the 
aggregate formation is completely absent in the presence of urea. However, the aggregation growth 
is greatly inhibited. Furthermore, the isothermal aggregation of the unfolded protein in presence of 9 
M urea was very slow at 25 ⁰C measured by the change in the apparent hydrodynamic radius of the 
samples with dynamic light scattering (Figure S12).   
Moderate isothermal aggregation of partially unfolded mAbs was already reported in the presence of 
another denaturant - guanidine hydrochloride50,62. This confirms that the aggregation of the proteins 
unfolded in the presence of urea is suppressed in comparison to aggregation induced by high 
temperatures. Noteworthy, the moderate aggregation in urea allows a large fraction of the (partially) 
unfolded protein to remain monomeric and allows the observation of formulation-dependent 
differences based on the relative monomer yield after refolding. 
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Figure 4. Thermal unfolding traces (left) and aggregation during unfolding (right) of LMU-1 in 
presence of different concentrations of urea. The buffer is 10 mM citrate pH 6.5. The samples were 
incubated for 24 hours in the urea before the measurements. The concentration of LMU-1 in all 
samples is 1 g/L. 
 
 
3.4. The samples after isothermal unfolding/refolding have native-like near-UV circular dichroic 
spectra and increased intermolecular beta sheet content  
The near-UV CD spectra of both proteins show typical spectra arising from the signals of the 
tryptophan, tyrosine, phenylalanine and disulphide bonds having a certain environment in the tertiary 
protein structure (Figure 5 and Figure S13)63–65. The formulation conditions (i.e. pH, buffer type and 
sodium chloride concentration) of the native samples do not affect the characteristics of the spectra – 
positive peak around 295 nm and several negative peaks between 280 and 250 nm. The near-UV CD 
spectra of LMU-1 and PPI03 samples incubated in 9.5 M urea do not contain most of the features of 
the native samples (Figures 5 and S13). Interestingly, the proteins in the supernatant of the refolded 
samples from the ReFOLD assay have the typical components of the near-UV CD spectra of the native 
monomers (Figures 5 and S13). Hawe et al. reported that the near-UV CD spectra of a heat or freeze-
stressed mAbs resemble the native protein66. Another group showed that the near-UV spectra of 
thermally-induced mAb oligomers resemble the spectra of the native protein67. Additionally, the near-
UV spectra of a mAb exhibited the same changes during thermal unfolding like the changes we 
observed during urea-induced isothermal unfolding68. 
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Figure 5. Near-UV CD spectra of LMU-1 - native (green solid line), unfolded with 10 M urea (yellow 
dot and dash) and refolded protein (red dot) after the ReFOLD assay was performed with 10 mM 
histidine pH 5 (A), 10 mM histidine pH 6.5 (B), 10 mM citrate pH 5 (C) and 10 mM citrate pH 6.5 (D). 
The CD spectra of the refolded samples represent the mixture of protein aggregates and monomer 
after refolding without any prior fractionation. 
 
Further, we used FTIR to investigate the secondary protein structure of the native and refolded protein.  
A minimum around 1638 cm-1 is observed in the Amide I region of the second-derivative FTIR spectra 
of native LMU-1 samples (Figure 6). This is typical for a native beta-sheet secondary structure and is 
already reported for monoclonal antibodies69–71. The refolded LMU-1 samples show a minimum in the 
Amide I band which is shifted to 1630 cm-1. The latter is typical when intermolecular beta-sheets are 
formed69–71. The above-mentioned observations were consistent among various formulation 
conditions we tested in this work. The intermolecular beta-sheets are an often-reported secondary 
structure of non-native protein aggregates72–74.  
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Figure 6. FTIR second derivative spectra of native and refolded LMU-1 after the ReFOLD assay was 
performed with 10 mM histidine pH 5 (A), 10 mM histidine pH 6.5 (B), 10 mM citrate pH 5 (C) and 10 
mM citrate pH 6.5 (D). The CD spectra of the refolded samples represent the mixture of protein 
aggregates and monomer after refolding without any prior fractionation. 
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4. CONCLUSIONS 
This work presents a novel perspective on how to quickly select formulation conditions that will 
suppress the formation of protein aggregates during long-term storage at 4 ⁰C and 25 ⁰C. The proposed 
approach is based on the hypothesis that formulation conditions which suppress the isothermal 
aggregation of various partially folded species would be formulation conditions that suppress protein 
aggregation during long-term storage. An isothermal microdialysis-based unfolding/refolding assay, 
named ReFOLD, is presented and used to assess the relative monomer yield after isothermal 
unfolding/refolding with 10 M urea of two mAbs, each in 12 different formulation conditions. The 
relative monomer yield of the proteins in different formulation conditions from the ReFOLD assay 
shows a very strong to strong correlation with the amount of aggregates formed by the proteins after 
storage for 12 months at 4 ⁰C and 25 ⁰C. Other stability-indicating parameters like the apparent protein 
melting temperatures and aggregation onset temperatures show inverse or weak correlations with the 
amount of aggregates formed after storage. The refolded protein samples have a native-like near-UV 
circular dichroic spectra and a peak position in the Amide I band which is typical for aggregated beta-
sheets.   
The concept of the ReFOLD assay presented herein opens several directions for future work. First, the 
ReFOLD assay must be tested with more proteins and on a larger set of formulation conditions to study 
whether the technique can be used as a universal tool for formulation development. Second, it will be 
interesting to study in detail the effect of various excipients, i.e. sugars, polyols, amino acids, 
surfactants, on the relative monomer yield of different proteins and investigate whether excipients 
that inhibit the aggregation of partially folded species are the excipients that stabilize the proteins 
during long-term storage. Third, the aggregates and monomers formed after unfolding and refolding 
in urea can be fractionated and their morphology and structure can be studied more in detail. It would 
be interesting to see whether the aggregates formed during long-term storage exhibit the same 
characteristics with the aggregates formed after refolding. Finally, the development of dedicated 
devices for fully automated and controlled microdialysis with online detection of aggregation and 
protein unfolding will pave the way for a more comprehensive understanding of the concept behind 
the ReFOLD assay.  
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Determination of aggregation onset temperature with dynamic light scattering 
25 µL of protein solution was filled in a 384 well plate (Corning) and the plate was centrifuged at 2200 
rpm for 2 minutes using a Heraeus Megafuge 40 centrifuge equipped with an M-20 well plate rotor 
(Thermo Fisher Scientific, Wilmington, USA). Next, a drop of silicone oil was used to seal each well and 
the samples were centrifuged again at 2200 rpm for 2 minutes. Unless otherwise stated, the well plate 
was placed in a Dyna Pro DLS plate reader (Wyatt Technology, Santa Barbara, USA) and a temperature 
ramp of 0.25 °C/min was applied from 25 to 80 °C. During the temperature ramp, the samples were 
measured with 3 acquisitions of 3 seconds. The autocorrelation function (ACF) of each sample was 
calculated from the fluctuation of the light scattering intensity using the Dynamics V7.8 software. 
Cumulant analysis was performed with the same software to derive the apparent coefficient of self-
diffusion (D) and the polydispersity index (PDI). Next, the apparent protein hydrodynamic radius from 
DLS (Rh) was calculated using the Stokes-Einstein equation. The aggregation onset temperature (Ton) 
from the increase in the Rh from DLS was determined using the Dynamics V7.8 software. All 
measurements were performed in triplicates. 
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Table S1. Relative Monomer Yield (RMY) of LMU-1 formulations after the ReFOLD assay and the 
relative content of high molecular weight species after long term storage of the respective LMU-1 
formulations  
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
1 10 histidine 5 0.401 0.387 0.372 0.21 0.23 0.18 0.11 0.14 0.21 
2 10 histidine 5.75 0.378 0.365 0.390 0.15 0.18 0.17 0.25 0.17 0.17 
3 10 histidine 6.5 0.269 0.272 0.265 0.38 0.55 0.41 0.27 0.21 0.37 
4 10 citrate 5 0.239 0.243 0.240 0.47 0.53 0.53 0.34 0.30 0.30 
5 10 citrate 5.75 0.17 0.164 0.169 0.79 0.66 0.72 0.32 0.43 0.34 
6 10 citrate 6.5 0.153 0.166 0.157 0.91 0.85 1.06 0.57 0.65 0.60 
7 50 histidine 5 0.098 0.097 0.092 0.67 0.72 0.72 0.43 0.47 0.51 
8 50 histidine 5.75 0.082 0.079 0.088 0.87 0.89 0.83 0.54 0.67 0.55 
9 50 histidine 6.5 0.003 0.009 0.002 1.66 1.61 1.55 0.90 0.93 0.94 
10 50 citrate 5 0.065 0.074 0.074 0.93 0.93 1.07 0.39 0.51 0.41 
11 50 citrate 5.75 0.036 0.030 0.039 1.08 1.13 1.24 0.57 0.61 0.60 
12 50 citrate 6.5 0.022 0.023 0.017 1.68 1.73 1.86 1.08 1.02 0.93 
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Table S2. Relative Monomer Yield (RMY) of PPI03 formulations after the ReFOLD assay and the 
relative content of high molecular weight species, i.e. protein aggregates, after long term storage* 
of the respective PPI03 formulations. The concentration of PPI03 is 5 g/L in all 12 formulations.  
Form. 
number 
Buffer pH NaCl RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
1 histidine 5 No 0.519 0.535 0.553 0.11 0.11 0.14 0.16 0.16 0.14 
2 histidine 5.75 No 0.47 0.47 0.495 0.15 0.13 0.13 0.15 0.13 0.14 
3 histidine 6.5 No 0.514 0.474 0.461 0.18 0.18 0.18 0.14 0.16 0.16 
4 histidine 5 70 mM 0.352 0.359 0.355 0.22 0.24 0.26 0.17 0.16 0.17 
5 histidine 5.75 70 mM 0.334 0.338 0.335 0.23 0.24 0.24 0.17 0.17 0.17 
6 histidine 6.5 70 mM 0.336 0.305 0.317 0.41 0.46 0.43 0.24 0.26 0.24 
7 citrate 5 No 0.418 0.417 0.397 0.5 0.44 0.43 0.24 0.23 0.22 
8 citrate 5.75 No 0.303 0.294 0.296 0.55 0.48 0.46 0.31 0.33 0.32 
9 citrate 6.5 No 0.255 0.284 0.285 0.65 0.67 0.64 0.56 0.54 0.54 
10 citrate 5 70 mM 0.431 0.399 0.421 0.5 0.45 0.48 0.24 0.23 0.22 
11 citrate 5.75 70 mM 0.364 0.339 0.323 0.41 0.44 0.44 0.29 0.3 0.29 
12 citrate 6.5 70 mM 0.337 0.346 0.353 0.63 0.63 0.6 0.55 0.55 0.56 
*The relative content of high molecular weight species of PPI03 after storage was measured with the same SEC 
method described in materials and methods. However, the elution of the protein was detected with a Dionex 
RF2000 fluorescence detector (Thermo Fisher, Dreieich, Germany) using the following parameters - excitation at 
280 nm, emission at 343 nm, gain 4.0 and medium sensitivity. There is a linear correlation (R2>0.98) between the 
relative area of high molecular weight species of PPI03 detected by UV absorption at 280 nm and by intrinsic 
fluorescence (data not shown). However, in the case of PPI03 many of the samples contained less than 0.2 % 
aggregates and the use of the fluorescence detector provided a better signal-to-noise ratio compared to the UV 
detector. 
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Table S3. Monomer recovery of LMU-1 after 12 months of storage at 25 ⁰C and 4 ⁰C. The monomer 
recovery was calculated by dividing the area of the monomer peak in the SEC chromatograms after 12 months 
of storage by the area of the monomer peak at the beginning of the stability study, and finally multiplying this 
value by 100. A value of 100 % therefore indicates that the same monomer area was fond after storage, while a 
value lower than 100 % indicates that the area of the monomer was smaller. 
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH SEC monomer recovery 
(%) after 12 months at 
25 ⁰C 
SEC monomer 
recovery (%) after 12 
months at 4 ⁰C 
Mean StDev Mean StDev 
1 10 histidine 5 99.96 0.05 100.54 0.22 
2 10 histidine 5.75 100.91 1.46 100.24 0.08 
3 10 histidine 6.5 100.43 1.14 99.99 0.14 
4 10 citrate 5 101.23 0.65 101.18 0.20 
5 10 citrate 5.75 100.15 0.66 100.13 0.38 
6 10 citrate 6.5 99.94 0.17 100.02 0.18 
7 50 histidine 5 96.15 1.17 99.50 0.54 
8 50 histidine 5.75 96.34 0.41 99.56 0.25 
9 50 histidine 6.5 95.48 1.20 99.06 0.26 
10 50 citrate 5 95.29 1.05 97.94 0.24 
11 50 citrate 5.75 95.38 0.51 98.36 0.41 
12 50 citrate 6.5 95.36 0.22 97.68 0.77 
 
Table S4. Monomer recovery of PPI03 after 12 months of storage at 25 ⁰C and 4 ⁰C. The monomer 
recovery was calculated by dividing the area of the monomer peak in the SEC chromatograms after 12 months 
of storage by the area of the monomer peak at the beginning of the stability study, and finally multiplying this 
value by 100. A value of 100 % therefore indicates that the same monomer area was fond after storage, while a 
value lower than 100 % indicates that the area of the monomer was smaller. 
Formulation 
number 
Buffer pH NaCl 
SEC monomer  
recovery (%) after  
12 months at 25 ⁰C 
SEC monomer recovery 
(%) after  
12 months at 4 ⁰C 
Mean StDev Mean StDev 
1 histidine 5 No 99.57 0.57 100.15 0.36 
2 histidine 5.75 No 98.87 0.37 99.48 0.20 
3 histidine 6.5 No 99.14 0.10 98.97 0.40 
4 citrate 5 70 mM 98.39 0.08 98.88 0.24 
5 citrate 5.75 70 mM 99.21 1.50 98.77 0.45 
6 citrate 6.5 70 mM 98.80 0.34 98.99 0.18 
7 histidine 5 No 96.91 0.34 98.67 0.36 
8 histidine 5.75 No 96.86 0.35 97.82 0.37 
9 histidine 6.5 No 98.11 0.60 98.47 0.35 
10 citrate 5 70 mM 96.78 0.45 98.19 0.62 
11 citrate 5.75 70 mM 96.76 0.92 96.86 0.55 
12 citrate 6.5 70 mM 98.32 0.53 98.67 0.79 
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Figure S1. Representative chromatograms of LMU-1 and PPI03 obtained with the size-exclusion 
chromatography method used during the long-term stability studies. The area of high molecular 
weight (HMW) species is integrated between 5 and 15.1 minutes retention time. The protein 
monomer is integrated between 15.1 and 22 minutes. 
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Figure S2. Subvisible particles in the LMU-1 and PPI03 formulations after 12 months of storage at  
25 ⁰C. The numbers represent cumulative particles larger than 2 µm in 1 mL. After 12 months of 
storage at 4 ⁰C, all formulations contained less than 5000 particles ≥ 2 µm per mL (data not shown). 
The measurements were performed with a FlowCAM® 8100 (Fluid Imaging Technologies, Inc., 
Scarborough, ME, USA). The system was equipped with a 10x magnification cell (81 µm x 700 µm). 
Before each measurement, the cleanliness of the cell was checked visually. 200 µL of sample were used 
for the analysis and the images are collected with a flow rate of 0.15 mL/min, auto image frame rate 
of 29 frames/second and a sampling time of 74 seconds. The following settings were used for particle 
identification - 3 µm distance to the nearest neighbour, particle segmentation thresholds of 13 and 10 
for the dark and light pixels respectively. The particle size was reported as the equivalent spherical 
diameter (ESD). The VisualSpreadsheet® 4.7.6 software was used for data collection and evaluation. 
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Figure S3. Correlation between the first melting temperature Tm1 of LMU-1 and the relative content 
of high molecular weight species detected by size exclusion chromatography after 12 months of 
storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid 
red line is linear fit of the data, the dark red zone represents the 95 % confidence interval of the fit 
and the light red zone the 95 % prediction interval. 
 
  
Figure S4. Correlation between the second melting temperature Tm2 of LMU-1 and the relative 
content of high molecular weight species detected by size exclusion chromatography after 12 
months of storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. 
The solid red line is linear fit of the data, the dark red zone represents the 95 % confidence interval 
of the fit and the light red zone the 95 % prediction interval. 
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Figure S5. Correlation between the aggregation onset temperature from DLS of LMU-1 and the 
relative content of high molecular weight species detected by size exclusion chromatography after 
12 months of storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the 
graph. The solid red line is linear fit of the data, the dark red zone represents the 95 % confidence 
interval of the fit and the light red zone the 95 % prediction interval. 
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Figure S6. Correlation between the relative monomer yield of PPI03 from the ReFOLD assay and the 
relative content of high molecular weight species detected by size exclusion chromatography after 
12 months storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the 
graph. The solid red line is linear fit of the data, the dark red zone represents the 95 % confidence 
interval of the fit and the light red zone the 95 % prediction interval. 
 
 
Figure S7. Correlation between the first melting temperature Tm1 of PPI03 and the relative content 
of high molecular weight species detected by size exclusion chromatography after 12 months of 
storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid 
red line is linear fit of the data, the dark red zone represents the 95 % confidence interval of the fit 
and the light red zone the 95 % prediction interval. 
 
 
34 
 
Figure S8. Correlation between the second melting temperature Tm2 of PPI03 and the relative content 
of high molecular weight species detected by size exclusion chromatography after 12 months of 
storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid 
red line is linear fit of the data, the dark red zone represents the 95 % confidence interval of the fit 
and the light red zone the 95 % prediction interval. 
 
 
Figure S9. Correlation between the aggregation onset temperature from DLS of PPI03 and the 
relative content of high molecular weight species detected by size exclusion chromatography after 
12 months of storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the 
graph. The solid red line is linear fit of the data, the dark red zone represents the 95 % confidence 
interval of the fit and the light red zone the 95 % prediction interval. 
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Figure S10. Isothermal unfolding curves of PPI03 in histidine (A) and citrate (B) buffer with different 
pH and different ionic strength. The symbols are means of triplicates and the bars represent the 
standard deviation. The lines are a guide to the eye. The concentration of LMU-1 in all samples is 
0.5 g/L. 
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Fig S11. Thermal unfolding traces (left) and aggregation during unfolding (right) of PPI03 in 
presence of different concentrations of urea. The buffer is 10 mM histidine pH 6.5 with 70 mM 
sodium chloride. The concentration of LMU-1 in all samples is 0.5 g/L. 
 
Figure S12. Isothermal aggregation of LMU-1 in presence of 9 M urea in different formulation 
conditions measured by the change in the apparent protein hydrodynamic radius from DLS. The 
samples are prepared, measured and evaluated as described in the Supplementary data. The 
measurements are performed at 25 ⁰C with 5 acquisitions of 5 seconds. The samples are corrected 
for viscosity using a value of 1.93 cP for the 9 M urea solutions. 
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Figure S13. NearUV CD spectra of PPI03 native (green solid line), unfolded with 10 M urea (yellow 
dot and dash) and refolded protein (red dot) after the ReFOLD assay was performed with 10 mM 
histidine pH 5 (A), 10 mM histidine pH 6.5 (B), 10 mM citrate pH 5 (C) and 10 mM citrate pH 6.5. 
 
 
